Business Combinations and Contingent Consideration (Tables)

12 Months Ended

Dec. 31, 2016

Talon Therapeutics, Inc. [Member]

Business Acquisition [Line Items]

Change in Fair Value of Contingent Consideration Related to Acquisition

Adjustments to CVR fair value are recognized within “change in fair value of contingent consideration related to acquisitions” in the accompanying Consolidated Statements of Operations.

	Fair Value of Talon CVR
December 31, 2015	$	1,377
Fair value adjustment for the year ended December 31, 2016	(124		)
December 31, 2016	$	1,253

Acquisition-Date Fair Value of Consideration Transferred

The acquisition-date fair value of the consideration transferred consisted of the following:

Cash consideration	$	3,000
Ligand Contingent Consideration	4,700
Total purchase consideration	$	7,700

Melphalan License [Member]

Business Acquisition [Line Items]

Change in Fair Value of Contingent Consideration Related to Acquisition

	Fair Value of Ligand Contingent Consideration
December 31, 2015	$	5,227
Fair value adjustment for the three months ended March 31, 2016	773
Payment to Ligand in April 2016 for FDA approval milestone achievement	(6,000		)
December 31, 2016	$	—

Summary of Allocation of Total Purchase Price to Net Assets Acquired

The allocation of the total purchase price to the net assets acquired is as follows:

IPR&D EVOMELA rights $ 7,700